Back to News
Sep 19, 2025 4:00 PM

Johnson & Johnson's Tecvayli-Darzalex Combo Shows 100% Response In Newly Diagnosed Myeloma Patients

Johnson & Johnson (NYSE:JNJ) on Friday announced that an investigational immune-based induction regimen with Tecvayli (teclistamab) and Darzalex Faspro (daratumumab and hyaluronidase) demonstrated meaningful clinical efficacy in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM).

Forty-nine patients were treated across three treatment cohorts, with a steroid-sparing approach, including regimens of Tecvayli with Darzalex Faspro and lenalidomide, with and without bortezomib.

Overall response (≥partial response) was achieved by 100% of patients in all treatment arms following induction therapy.

Of 46 minimal residual disease (MRD)-evaluable patients with available samples ...